Sign In
Buy KVUE
$16.83
-0.490 (-2.83%)
At Close: Jun 03, 2026
Kenvue is a “show me story” after strong start following J&J spinoff
02:45pm, Tuesday, 30'th May 2023
UBS analysts initiated coverage of Kenvue Inc (KVUE), the recent spinoff of Johnson & Johnson (NYSE:JNJ)'s consumer brand segment, with a ‘Neutral' rating and a 12-month target price of $28 per shar
7 Consumer Stocks to Buy and Hold for the Long Haul
07:15pm, Monday, 29'th May 2023
When it comes to building a strong portfolio, it's wise to include some of the best long-term consumer stocks. In fact, there are two key reasons for this.
Kenvue Just IPO'd, but Is the Stock a Buy?
05:24am, Friday, 19'th May 2023
Kenvue is now independent of Johnson & Johnson (sort of). It needs to demonstrate that nothing important has changed since the spinoff.
2 Dividend Stocks to Double Up On Right Now
08:35am, Wednesday, 17'th May 2023
Falling share prices have pushed up the dividend yields on several high-quality companies. Johnson & Johnson currently yields around 3%.
Kenvue Has Gone Public: Should You Buy the Stock?
09:38am, Tuesday, 16'th May 2023
Shares of Kenvue went public last week as Johnson & Johnson spun off its consumer health business. The new company markets some strong brands, including Tylenol, Nicorette, Motrin, and many others.
J&J Kenvue Spinoff Aims To Give Investors A Healthy Return
07:48am, Tuesday, 09'th May 2023
This year hasn't been the most active when it comes to initial public offerings, but Johnson & Johnson NYSE: JNJ spinoff Kenvue Inc. NYSE: KVUE set a bar, of sorts, with the biggest IPO since Rivian A
U.S. IPO Weekly Recap: Kenvue And ACELYRIN Fire Up The IPO Market, Raising A Combined $4.3 Billion
08:08am, Sunday, 07'th May 2023
The month of May started off with two large IPOs, Kenvue and ACELYRIN. Two blank check IPOs also priced this past week.
Kenvue: A Look At The Johnson Spinoff
05:59pm, Friday, 05'th May 2023
Kenvue Inc. has been spun off from Johnson & Johnson in a rather large IPO. The spinoff was well-received by the market, being the world's largest pure-play consumer health play.
ETFs to Bet on the Successful Debut of Kenvue
12:55pm, Friday, 05'th May 2023
Kenvue is the world's largest pure-play consumer health company by revenue, and makes well-known products, including Tylenol, Neutrogena, Listerine, Johnson???s', Band-Aid, Aveeno, Zyrtec and Nicorett
Kenvue stock slips on second day of trading
12:16pm, Friday, 05'th May 2023
Yahoo Finance Live's Julie Hyman discusses the decline in stock for Kenvue.
Kenvue CEO looks to brand, product innovation to drive growth after IPO
09:40am, Friday, 05'th May 2023
Kenvue CEO Thibaut Mongon said the spinoff's portfolio of brands, which includes Band-Aid, Tylenol and Neutrogena, has "ample opportunity" to grow.
Kenvue Stock Surges On Trading Debut
09:00am, Friday, 05'th May 2023
Kenvue Inc. is defensive and resilient to macro shocks. The company owns a portfolio of well-established brands.
J&J's Kenvue: Unlocking Value in a Stagnant Market
06:13pm, Thursday, 04'th May 2023
2023 has been a pretty slow year as far as initial public offerings go, but pharmaceutical giant Johnson & Johnson ( JNJ , Financial) bucked the trend on Thursday by offering its consumer health divis
Johnson & Johnson Spinoff Kenvue Valued at $41 Billion in IPO
03:25pm, Thursday, 04'th May 2023
Johnson & Johnson's consumer healthcare spinoff has made the biggest U.S. initial public offering (IPO) since 2021. Kenvue, which includes Band-Aid and several other well-known consumer brands that ha
Kenvue IPO: Profitable Company, Expensive Stock
03:02pm, Thursday, 04'th May 2023
At its expected valuation, KVUE looks fully valued and does not provide investors with much upside potential.
